Brandon Capital is a Melbourne-based life sciences venture capital firm founded to support the development and commercialization of groundbreaking biomedical technologies across Australasia and beyond. With offices in Australia, New Zealand, the United States, and the United Kingdom, the firm has become a leading force in the region’s biotech and health innovation landscape. Brandon Capital combines deep domain expertise with strong institutional and governmental partnerships, helping early-stage scientific discoveries evolve into commercial successes.
The firm specializes in investing in early-stage and emerging biomedical technologies with significant commercial and therapeutic potential.
Its core areas of focus include oncology, radiopharmaceuticals, drug delivery systems, antibody-drug conjugates (ADCs), implants, and other novel therapeutics.
Brandon Capital operates across the translational spectrum, with a particular emphasis on supporting spinouts from top research institutions in Australia and New Zealand. The firm’s proprietary deal flow is strengthened by its connection to Brandon BioCatalyst, a consortium of over 50 medical research organizations.
In July 2025, Brandon Capital announced the close of its sixth fund, BioCatalyst Fund Six (BB6), at over A$439 million. The fund received backing from existing institutional investors including HESTA, Hostplus, CSL, and QIC, as well as public entities such as the Western Australian Government and the National Reconstruction Fund Corporation (NRFC), Australia’s sovereign manufacturing investor.
The new fund brings Brandon Capital’s total assets under management to over A$1 billion.
Leadership
Brandon Capital is led by co-founder and Managing Partner Chris Nave, a recognized leader in life sciences venture capital across Australasia. Under his leadership, the firm has built a robust investment team with deep expertise in biotech, pharma, clinical development, and commercialization. The firm’s multinational presence supports global scalability and facilitates clinical and regulatory pathways across different jurisdictions.
Investment Strategy
Brandon Capital takes a hands-on, long-term approach to venture investing. It works closely with research institutions, leveraging the Brandon BioCatalyst platform to identify and support high-potential biomedical innovations from inception to commercialization.
The firm provides capital, strategic guidance, and corporate infrastructure that allows scientists and technical founders to focus on research and development.
Brandon’s strategy includes advancing companies through preclinical and clinical stages, while also contributing to the development of Australia's sovereign biotech and advanced manufacturing capabilities.
Notable Investments
Fund Six investments include:
Brandon’s broader portfolio comprises over 30 active companies, with 17 currently in clinical trials and several already in or near market.
Notable Exits
While recent exits were not detailed in the announcement of Fund Six, Brandon Capital has a long track record of supporting companies from inception through to clinical validation and strategic acquisition or public offering. Previous funds have contributed to several landmark deals in Australian and international biotech.
Other
Brandon Capital plays a strategic role in developing Australia and New Zealand’s life sciences ecosystem, both through its investments and its role in mobilizing institutional and government support for the sector.
Its structure allows portfolio companies to operate with minimal administrative overhead, focusing instead on translating research into real-world medical advances.
The firm is also actively involved in building out Australia’s sovereign capabilities in high-skill biotech manufacturing.
